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HIV-1 infection disproportionately affects women in sub-Saharan Africa, where areas of
high HIV-1 prevalence and Schistosoma haematobium endemicity largely overlap. Female
genital schistosomiasis (FGS), an inflammatory disease caused by S. haematobium egg
deposition in the genital tract, has been associated with prevalent HIV-1 infection.
Elevated levels of the chemokines MIP-1a (CCL-3), MIP-1b (CCL-4), IP-10 (CXCL-10),
and IL-8 (CXCL-8) in cervicovaginal lavage (CVL) have been associated with HIV-1
acquisition. We hypothesize that levels of cervicovaginal cytokines may be raised in
FGS and could provide a causal mechanism for the association between FGS and HIV-1.
In the cross-sectional BILHIV study, specimens were collected from 603 female
participants who were aged 18–31 years, sexually active, not pregnant and participated
in the HPTN 071 (PopART) HIV-1 prevention trial in Zambia. Participants self-collected
urine, and vaginal and cervical swabs, while CVLs were clinically obtained. Microscopy
and Schistosoma circulating anodic antigen (CAA) were performed on urine. Genital
samples were examined for parasite-specific DNA by PCR. Women with FGS (n=28),
defined as a positive Schistosoma PCR from any genital sample were frequency age-
matched with 159 FGS negative (defined as negative Schistosoma PCR, urine CAA, urine
microscopy, and colposcopy imaging) women. Participants with probable FGS (n=25)
(defined as the presence of either urine CAA or microscopy in combination with one of four
clinical findings suggestive of FGS on colposcope-obtained photographs) were also
included, for a total sample size of 212. The concentrations of 17 soluble cytokines and
chemokines were quantified by a multiplex bead-based immunoassay. There was noorg March 2021 | Volume 12 | Article 6206571
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without FGS. An exploratory analysis of those women with a higher FGS burden, defined
by ≥2 genital specimens with detectable Schistosoma DNA (n=15) showed, after
adjusting for potential confounders, a higher Th2 (IL-4, IL-5, and IL-13) and pro-
inflammatory (IL-15) expression pattern in comparison to FGS negative women, with
differences unlikely to be due to chance (p=0.037 for IL-4 and p<0.001 for IL-5 after
adjusting for multiple testing). FGS may alter the female genital tract immune environment,
but larger studies in areas of varying endemicity are needed to evaluate the association
with HIV-1 vulnerability.Keywords: HIV-1, female genital schistosomiasis, S. haematobium, inflammation, sub-Saharan Africa, genital tract,
cervicovaginal lavage (CVL), polymerase chain reaction (PCR)INTRODUCTION
HIV-1 infection disproportionately affects women in sub-
Saharan Africa (1), where areas of high HIV-1 prevalence and
Schistosoma haematobium endemicity largely overlap (2).
Female genital schistosomiasis (FGS), caused most frequently
by S. haematobium egg deposition in the genital tract, has been
associated with prevalent HIV-1 infection in cross-sectional
studies (3). The presence of S. haematobium eggs in genital
tissue is also associated with vascularization (4) and the
accumulation of CD4+ lymphocytes and macrophages (5),
making the granuloma-associated environment a potential
contributor to HIV-1 vulnerability. In addition to modulation
of the local cervicovaginal environment, FGS has also been
associated with a higher frequency of systemic CD4 T-cells
expressing the chemokine receptor CCR5 (6). Tissue-entrapped
eggs are also associated with clinically visible FGS-associated
manifestations in the cervicovaginal mucosa (7). FGS lesions
may breach the intact cervicovaginal immune barrier and are
hypothesized to provide an entry point for HIV-1 infection (2,
3). However, the underlying mechanism for potential HIV-1
vulnerability in FGS has not been fully characterized and
requires further investigation.
The presence of S. haematobium eggs in human tissue
commonly provokes an inflammatory response (5).
Cervicovaginal inflammation has emerged as an important risk
factor for HIV-1 acquisition, with the presence of increased
chemotactic cytokine concentrations, specifically macrophage
inflammatory protein-1a (MIP-1a [CCL-3]), MIP-1ß [CCL-4],
interleukin (IL)-8 [CXCL-8], and interferon-g inducible protein-
10 (IP-10 [CXCL-10]), conferring increased risk (8). Broadly,
while pro-inflammatory cytokines are central in recruiting and
activating HIV-1 target cells, they also propagate a cascade of
downstream cellular processes that enact functions central to
HIV-1 pathogenesis (9). The presence of pro-inflammatory
cytokines in the female genital tract may also be associated
with HIV-1 replication (via stimulation of transcription
factors) (10), an increased frequency and activation of HIV-1
target cells (9, 11, 12) and proteomic signatures suggestive of
tissue remodeling that may compromise cervicovaginal barrier
function (12).org 2Sexually transmitted infection (STI) and a “non-optimal”
cervicovaginal microbiota contribute to a vaginal pro-
inflammatory environment (11, 13), and are thus important risk
factors for HIV-1 acquisition (14, 15), but elevated cervicovaginal
cytokine and chemokine levels have also been detected in their
absence (8). In addition to STI and cervicovaginal microbiota, a
number of additional biological and behavioral factors influence
the levels of detectable soluble immune proteins in the female
genital tract, including the presence of semen (16), cervical ectopy
(16), use of hormonal contraception (17), menstrual cycle (18),
and intravaginal cleansing practices (13, 17).
FGS may be an unmeasured co-factor contributing to
cervicovaginal inflammatory signatures in endemic sub-Saharan
African populations (8, 11). S. haematobium infection, in the
absence of evaluation for genital involvement, has been associated
with altered levels of systemic (19) and cervicovaginal cytokines
(20). While male genital schistosomiasis has been associated with
elevated seminal fluid cytokine concentrations (21), little is known
regarding the human cervicovaginal environment in FGS or the
role of the immune response. We hypothesize that FGS modulates
the cervicovaginal immune environment and that evidence of
FGS-associated cervicovaginal inflammation may provide insight
into a causal mechanism for the association between FGS and
HIV-1. In this cross-sectional study, we evaluate cervicovaginal
cytokines and chemokines in women with and without FGS.METHODS
Study Setting and Participants
The cross-sectional bilharzia and HIV (BILHIV) study was
nested in HPTN 071 (PopART), a cluster randomized trial to
measure the impact of an HIV-1 combination prevention
package (22). HIV-1 incidence was measured in an HPTN 071
(Pop-ART) Population Cohort comprised of one randomly
selected adult (18 to 44 years of age) from a random sample of
households in each community who provided data and blood
samples at baseline, 12, 24, and 36 months (22). After the 36-
month HPTN 071 (PopART) visit, trained community workers
made home visits between January and August 2018 to women
who had expressed interest in the BILHIV study (23). WomenMarch 2021 | Volume 12 | Article 620657
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active, and resident in one of the two urban communities that
participated in HPTN 071 (PopART) in Livingstone, Zambia.
Following written informed consent, the BILHIV study home
visit included a questionnaire, genital self-sampling (cervical and
vaginal), and a urine specimen, as previously described (23).
Clinic-Based Sample Collection
Within days of self-sampling, enrolled women who were not
currently menstruating were invited to attend Livingstone
Central Hospital cervical cancer screening clinic, where one of
two trained midwives performed a cervicovaginal lavage (CVL).
Cervicovaginal images were captured with a portable colposcope
(MobileODT, Tel Aviv, Israel) and were evaluated by one author
(EFK) for the presence of any of the four recognized FGS
cervicovaginal manifestations: homogenous yellow sandy
patches, grainy sandy patches, rubbery papules, and abnormal
blood vessels (24). Women having these manifestations (24) and
women with any positive urine or genital Schistosoma diagnostic
were treated free of charge with 40 mg/kg praziquantel. Testing
for STI was not performed at the point-of-care and participants
with suspected STI were offered syndromic management, as per
local guidelines (25).
CVL Specimen Processing
After speculum insertion, normal saline (10 ml) was flushed
continuously with a bulb syringe across the cervix and vaginal
walls for 1 min and collected from the posterior fornices. CVL
fluid was transferred to a 15 ml conical polypropylene tube and
stored temporarily in a refrigerator (4°C) on ice until transfer to
the laboratory. Protease inhibitor (Cocktail Set I, Calbiochem,
Merck Millipore, Darmstadt, Germany) was added to one 1.5 ml
aliquot for cytokine and chemokine testing and stored at −80°C, as
previously described (17). Specimens were stored for a maximum
of 20months (range 12–20) and were not previously thawed. After
thawing, specimens were centrifuged at 320g for 10 min and the
supernatant removed. CVL color was visually assessed and a 10 ml
aliquot was placed on a Hemastix test strip (Siemens, Erlangen,
Germany). As per the manufacturer’s instructions, CVL
hemoglobin concentrations were recorded after comparing the
test strip with color categories representing approximate quantities
of erythrocytes (ery) per µL: none, trace, low (25 ery/mL),
moderate (80 ery/mL), high (200 ery/mL) (17).
Multiplex Bead Based Assays
Luminex MAGPIX© was used to measure concentrations of
seventeen soluble cytokines and chemokines using MILLIPLEX
HumanCytokine/ChemokineMagnetic Bead kits (MerckMillipore,
Darmstadt, Germany) according to the manufacturer’s instructions
and recommendations for dilute samples, i.e. CVL. The
concentrations of eotaxin (CCL-11), interferon-gamma (IFN-g),
IL-10, IL-13, IL-15, IL-17A, IL-1a, IL-1b, IL-4, IL-5, IL-6, IL-8
(CXCL-8), IP-10 (CXCL-10), monocyte chemoattractant protein
(MCP-1) (CCL-2), MIP-1a, (CCL-3), MIP-1b (CCL-4) and tumor
necrosis factor-a (TNF-a) were measured in undiluted CVL in
duplicate. The lower limit of detection was between 0.26 and 5.66
pg/ml for the 17 cytokines and chemokines measured (S1 Table).Frontiers in Immunology | www.frontiersin.org 3Using a Luminex MAGPIX© bioanalyzer and xPONENT software
(version 4.2), the median fluorescent intensity was measured,
background-adjusted, and converted into analyte concentrations
using a 5 parameter logistic regression equation to interpolate
standard curves. To minimize between-plate variations in
cytokine and chemokine concentrations, two specimen controls
were included in duplicate across plates and equal proportions of
specimens with FGS, probable FGS, and FGS negative were
distributed across six 96-well plates (8). Cytokine or chemokine
concentrations below the lower limit of quantification (LLOQ) were
imputed to be the midpoint of the lowest concentration for each
analyte and zero and concentrations above the upper limit of
quantification were imputed as the highest concentration for
each analyte.
HIV-1
Laboratory-based fourth-generation HIV-1 testing (Abbott
Architect HIV Ag/Ab Combo Assay). was performed for
HPTN 071 (PopART) Population Cohort participants at each
study visit (22).
Circulating Anodic Antigen
A lateral flow assay utilizing up-converting reporter particles for
the quantification of CAA was performed on urine samples at the
Leiden University Medical Center (LUMC), as previously
described (23, 26). CAA levels reflect the burden of live
schistosomes and decline after successful treatment with
praziquantel (27, 28). Analyzing the equivalent of 417 µl urine
(wet reagent, UCAAhT417), a CAA value of >0.6 pg/ml was
considered positive (28).
PCR for Detection of Schistosoma DNA
DNA extraction and PCR set up was performed at LUMC, using a
custom automated liquid handling station (Hamilton,
Switzerland), as previously described (23). DNA was extracted
from 200 µl of specimen (cervical swab, vaginal swab, CVL): with
QIAamp spin columns (QIAGEN Benelux; Venlo, The
Netherlands). Detection of the schistosome-specific internal-
transcribed-spacer-2 (ITS2) target was performed by real-time
PCR as previously described (23, 29). This PCR does not
differentiate between Schistosoma species. DNA amplification
and detection were performed with the CFX96 Real Time PCR
Detection System (BioRad, California, USA). The output in cycle
quantification value (Cq), reflecting the parasite-specific DNA load
in the tested sample, was analyzed using BioRad CFX software.
Parasite DNA loads were categorized by the following pre-specified
Cq thresholds: high (Cq<30), moderate (30≤ Cq <35), low (35≤ Cq
<50) and negative (no Cq detected), as previously described (30).
STI Detection
We quantified Chlamydia trachomatis, Neisseria gonorrhoeae,
Mycoplasma genitalium, and Trichomonas vaginalis using the S-
DiaCTNG™ (for C. trachomatis and N. gonorrhea) and S-
DiaMGTV™ (for M. genitalium and T. vaginalis) (both
Diagenode Diagnostics, Seraing, Belgium) on DNA obtained
from cervical swabs at Ghent University (Ghent, Belgium)
according to the manufacturer’s instructions. Amplification wasMarch 2021 | Volume 12 | Article 620657
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Software Version 1.5 (Roche, Basel, Switzerland). To quantify each
of the target species, standard curves were constructed from a
tenfold dilution series of DNA from C. trachomatis, N.
gonorrhoeae, M. genitalium, and T. vaginalis. Genomic DNA of
C. trachomatis ATCC VR-571B, T. vaginalis ATCC 50148 and M.
genitalium G37 was obtained from the American Type Culture
Collection (ATCC). Genomic DNA from N. gonorrhoeae was
obtained after culturing strain ATCC 43069 at 35°C ±1°C for 5
days on chocolate agar (Becton Dickinson) and extracting DNA
from colonies using Roche High Pure DNA Purification kit
(Roche). All DNA concentrations were determined using
NanoDrop (Thermo Fisher scientific, Erembodegem, Belgium).
The genomic concentrations were calculated using the described
genomic sizes of the type strains. Both the standard curves and
samples were run in duplicate. The number of bacteria and
protozoan concentration was expressed as genome equivalents
per ml (geq/ml) (31).
Ethical Considerations
The study was approved by the University of Zambia Biomedical
Research Ethics Committee (reference 011-08-17), the Zambia
National Health Research Authority and the London School of
Hygiene and Tropical Medicine Ethics Committee (reference
14506). Permission to conduct the study was given by
Livingstone District Health Office and the superintendent of
Livingstone Central Hospital.
FGS Definitions
The FGS categories were defined by the results of four
investigations: Schistosoma PCR (on DNA extracted from
cervical swabs, vaginal swabs, or CVL), colposcopy imageFrontiers in Immunology | www.frontiersin.org 4review, urine CAA, and urine microscopy. Participants were
grouped by the outcomes of their diagnostic tests into three
mutually exclusive categories. FGS was defined as at least one
positive Schistosoma PCR on a genital specimen (cervical swab,
vaginal swab and/or CVL). In participants with a negative
Schistosoma PCR, probable FGS was defined as the presence of
urinary schistosomiasis, detected with either urine CAA or urine
microscopy, in combination with one of four clinical findings
suggestive of FGS on any colposcope-obtained photograph (24).
FGS negative was defined as negative results on all diagnostic
assays. Participants with results for all available diagnostic tests
who were Schistosoma genital PCR negative and did not qualify
for the FGS, probable FGS, or FGS negative groups (n=190) were
not eligible for study inclusion (Figure 1). All participants with
FGS (n=28) who attended clinic follow up and provided a CVL
specimen and all participants with probable FGS (n=25) were
selected for measurement of cytokines and chemokines in CVL
samples. Three FGS negative participants were selected for every
FGS and probable FGS participant, using a random number
generator. The FGS negative participants were frequency
matched by age to the participants with FGS.STATISTICAL METHODS
Participant characteristics were summarized by median and
interquartile range (IQR) for continuous variables, and by
frequency and percentage for categorical variables.
Differences in characteristics between the FGS categories
were evaluated using Fisher’s exact and chi-squared tests. For
cytokines or chemokines with at least 70% of sample results
above the LLOQ, differences in median cytokine or chemokineFIGURE 1 | Study Flow Diagram. Not visited (n=189)– the participant was not visited before the study closed for enrollment; Visited but not contacted (n=110)– a
visit was made to the study household, but the participant could not be located (70), had relocated (39), or died (1); Contacted & not immediately enrolled (n=120)–
visited but not recruited (42), out of town (18), declined to participate (60); Contacted & ineligible (n=41)– virgin (16), pregnant (17), over 31 (8).March 2021 | Volume 12 | Article 620657
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the Wilcoxon-Mann-Whitney test. Cytokines or chemokines
with <70% of the sample results above the LLOQ were
analyzed as binary variables (presence/absence) and
compared between FGS categories using Fisher’s exact and
chi-squared tests. To correct for multiple comparisons we used
a Monte Carlo simulation approach with 1000 replicates (32):
for each replicate the labels of the groups being compared were
randomly permuted and statistical tests were repeated, to
generate empirical p-values. For further analysis, cytokine or
chemokine concentrations with at least 70% of sample results
above the LLOQ were log-transformed to normalize their
distribution, and linear regression was performed to evaluate
the association between FGS and mean cytokines or
chemokine in univariable and multivariable analysis and
expressed with 95% confidence intervals. For the cytokines
with <70% of the sample results above the LLOQ (IL-5, IL-13,
IL-15, and TNF-a), logistic regression was used to evaluate the
assoc ia t ion between FGS and detec tab le cytok ine
concentrations and expressed with 95% confidence intervals.
To adjust for potential confounders, we developed a causal
conceptual framework (S1 Figure) to inform our minimal
adjustment set. For the cytokines and chemokines analyzed
by linear regression, we adjusted for age, education,
community of residence, and the presence of any STI. Since
hormonal contraception is associated with the outcome, but
not the exposure (FGS), it was also included in the
multivariable model to improve precision. For the cytokines
analyzed by logistic regression (IL-5, IL-13, IL-15, and TNF-
a), due to the relatively low number of participants with
concentrations above the LLOQ, these cytokines were
adjusted for age and STI. Because HIV-1 status and the
presence of hemoglobin in CVL are both potentially
influenced by FGS (2), and may also affect CVL cytokine or
chemokine concentrations, these variables were considered to
be on the causal pathway and were not included in the final
multivariable model (S1 Figure).
Our primary hypothesis was that FGS modulates the
cervicovaginal microenvironment with a secondary hypothesis
that FGS may increase the concentration of selected HIV-1
acquisition associated chemokines (8). Thus, our primary
analysis focused on the detection of Schistosoma DNA in the
genital tract, comparing FGS vs FGS negative participants. As a
secondary aim, participants with FGS and probable FGS were
combined and compared with the FGS negative group.
Spearman’s rank correlation was used to evaluate the strength
of the relationship between individual analytes (S2 Figure). Since
many cytokines and chemokines were correlated, we performed
Principal Components Analysis (PCA) on the log-transformed
analyte concentrations to generate new uncorrelated
“components” that were linear combinations of the initial
variables. The first two principal components captured the
majority of the variability in the data and were taken forward
for additional comparisons between FGS groups (S2 Table).
To evaluate the possible association between intensity of FGS
presentation and changes in cytokine or chemokine concentrations,Frontiers in Immunology | www.frontiersin.org 5two ad hoc exploratory analyses were performed: (1) participants
with ≥2 genital samples with detectable Schistosoma DNA levels
were compared with those in the FGS negative group, (2)
participants with a moderate/high genital Schistosoma DNA
concentration (defined by a Cq <35 in at least one of the three
examined samples) were compared with those in the FGS
negative group.
In this study we measured the concentration of cytokines and
chemokines in CVL. However, the presence of hemoglobin in
CVL may serve as a surrogate marker for the presence of
systemic and/or menstrual blood in the cervicovaginal
environment. HIV-1 status and the presence of hemoglobin in
CVL are potentially influenced by FGS (2), but may also
independently affect cytokines and chemokine concentrations.
Thus, we performed two sensitivity analyses, one compared
participants with FGS with those in the FGS negative group
after excluding the participants who were HIV-1 positive from
both groups. A second sensitivity analysis compared participants
with FGS with those in the FGS negative group after excluding
the participants whose CVL sample displayed the presence of
hemoglobin. Data were analyzed using STATA 15.1 (Stata
Corporation, College Station, TX). P-values less than 0.05 were
classified as demonstrating “evidence” of an association and p-
values between 0.05 and 0.10 were classified as demonstrating
“some evidence” of an association.RESULTS
A total of 603 eligible women were enrolled and 212 (35.2%)
were included in this study (Figure 1). Overall, 13.2% (28/212) of
women had FGS, defined by a positive genital Schistosoma PCR
from any of the following sites: 8.5% (18/212) cervical swab, 6.6%
(14/212) vaginal swab, and 6.6% (14/212) CVL. Probable FGS
was detected in 25 women, and 61.1% (159/262) of the women
who were negative on all diagnostic tests were randomly selected
for inclusion in this study.
Baseline Characteristics
The majority of the participants had received at least secondary
education, were using hormonal contraception, and had
detectable hemoglobin in their CVL. At the conclusion of
HPTN 071 (PopART), HIV-1 prevalence was 17.0% (36/212)
among the women included in this study and one-third of the
women had at least one STI (Table 1). Active schistosome
infection, defined as either a positive urine microscopy (11.8%,
25/212) or detectable CAA (20.2%, 43/212), was reported in
21.2% (45/212). A small proportion of women reported current
water contact, but more than half reported childhood
water contact.
There was strong evidence of a difference in community of
residence between FGS, probable FGS, and FGS negative
participants (p=0.001) with participants with FGS and probable
FGS more likely to live in Community A than participants in the
FGS negative group (Table 1). There were differences between
the three categories of FGS status for age (p<0.001), educationalMarch 2021 | Volume 12 | Article 620657
Sturt et al. FGS and Cervicovaginal Immune Activationattainment (p=0.04), employment (p=0.05), and marital status
(p=0.04) with participants in the probable FGS group more likely
to be older, have a primary school education, be employed, and
be married than FGS and FGS negative participants. Other
characteristics were similar by FGS status.Frontiers in Immunology | www.frontiersin.org 6Expression Profiles of Cytokines and
Chemokines in CVL
The mean, median and range of concentrations (pg/ml) of the 17
cytokines and chemokines measured are displayed in S1 Table.
The distributions of log-transformed concentrations (medianTABLE 1 | Baseline characteristics of the 212 study participants by female genital schistosomiasis (FGS) status.
Socio-behavioral Characteristics FGS* % (n = 28) FGS Probable* % (n = 25) FGS Negative* % (n = 159) p-value
Age in years Median (IQR) 22 (20–24) 27 (23–31) 23 (22–24) 0.001
Marital Status Single 42.9 (12) 16.0 (4) 45.9 (73) 0.04∫
Married or Cohabitating 57.1 (16) 80.0 (20) 50.9 (81)
Divorced or Separated 0.0 (0) 4.0 (1) 3.1 (5)
Education (highest level) None/Any Primary School 32.1 (9) 48.0 (12) 22.0 (35) 0.04∫
Any Secondary School 67.9 (19) 52.0 (13) 70.4 (112)
Training in a Trade 0.0 (0) 0.0 (0) 7.6 (12)
Employment Status Working 14.3 (4) 44.0 (11) 25.8 (41) 0.05
Not Working 85.7 (24) 56.0 (14) 74.2 (118)
Current Water Contact None 100.0 (28) 84.0 (21) 86.8 (138) 0.1∫
Any 0.0 (0) 16.0 (4) 13.2 (21)
Childhood Water Contact None 14.3 (4) 24.0 (6) 32.1 (51) 0.1
Any 85.7 (24) 76.0 (19) 67.9 (108)
Community of Residence Community A 75.0 (21) 80.0 (20) 41.5 (66) <0.001
Community B 25.0 (7) 20.0 (5) 58.5 (93)
Sexual behavior characteristics and STI
Ever pregnant No# 7.1 (2) 4.0 (1) 17.0 (27) 0.3∫
Yes 92.9 (26) 96.0 (24) 82.4 (131)
Age at sexual debut Median (IQR) 16 (15–18) 17 (15–18) 17 (16–18) 0.09
Lifetime sexual partners Median (IQR) 3 (2–4.5) 2 (1–3) 2 (1–4) 0.3
Currently Sexually Active No## 10.7 (3) 8.0 (2) 16.5 (26) 0.6∫
Yes 89.3 (25) 92.0 (23) 83.5 (132)
Contraceptive Method Implant 7.1 (2) 8.0 (2) 8.8 (14) 1.0∫
Injectable 53.6 (15) 48.0 (12) 47.8 (76) 0.9
Oral Contraceptive Pill 3.6 (1) 12.0 (3) 6.3 (10) 0.5∫
Condoms 10.7 (3) 20.0 (5) 16.4 (26) 0.7∫
HIV-1 Not Detected 82.1 (23) 80.0 (20) 83.7 (133) 0.9
Detected 17.9 (5) 20.0 (5) 16.4 (26)
Chlamydia trachomatis Not Detected 89.3 (25) 96.0 (24) 91.8 (146) 0.7∫
Detected 10.7 (3) 4.0 (1) 8.2 (13)
Neisseria gonorrhea Not Detected 100.0 (28) 96.0 (24) 92.4 (147) 0.4∫
Detected 0.0 (0) 4.0 (1) 7.6 (12)
Mycoplasma genitalium Not Detected 100.0 (28) 96.0 (24) 95.6 (152) 0.5∫
Detected 0.0 (0) 4.0 (1) 4.4 (7)
Trichomonas vaginalis Not Detected 67.9 (19) 68.0 (17) 78.6 (125) 0.3
Detected 32.1 (9) 32.0 (8) 21.4 (34)
Any STI Not Detected 64.3 (18) 56.0 (14) 67.3 (107) 0.5
Detected 35.7 (10) 44.0 (11) 32.7 (52)
Clinical Findings
Hemoglobin in CVL (ery/µL)ϑ None 28.6 (8) 25.0 (6) 36.1 (57) 0.3∫
Trace 17.9 (5) 12.5 (3) 15.2 (24)
25 32.1 (9) 16.7 (4) 17.7 (28)
80 3.6 (1) 16.7 (4) 17.1 (27)
200 17.9 (5) 29.2 (7) 13.9 (22)
Colposcopy Findingsϑϑ Sandy Patches 22.2 (6) 76.0 (19) 0.0 (0) N/A
Rubbery Papule 0.0 (0) 0.0 (0) 0.0 (0)
Abnormal Blood Vessels 22.2 (6) 24.0 (6) 0.0 (0)
No FGS findings 56.0 (15) 0.0 (0) 100.0 (159)March 2021 | Volume 12 | Article*FGS – Schistosoma PCR positive specimen from cervicovaginal lavage, vaginal swab or cervical swab; probable FGS– Schistosoma PCR negative and either positive circulating anodic
antigen (CAA) or urine microscopy and suggestive expert-reviewed colposcopy imaging; FGS negative – negative Schistosoma PCR and negative CAA and negative urine microscopy and
negative expert-reviewed colposcopy imaging.
∫Fisher’s exact test.
#Self-reported history of ever having a pregnancy, participants reporting “no answer” (n=1, FGS negative group) are not shown.
##Participants reporting “no answer” (n=1, FGS negative group) are not shown.
ϑHemoglobin was measured with Hemastix® test strips using a color chart measured in erythrocytes (ery) per µl.
ϑϑColposcopy findings were included in the study inclusion criteria, so no p-value is shown; one participant with FGS did not have interpretable colposcopy results. Images were
interpreted based on the presence of sandy patches or rubbery papules, if these findings were present, the additional finding of abnormal blood vessels was not noted.620657
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displayed by FGS status in Figure 2.
FGS Signature - Crude and Adjusted
Expression Profiles
Compared to FGS negative women, IL-5 was elevated in
participants with FGS (Table 2, Figure 2, crude p-value 0.02, p-
value after adjustment for multiple testing 0.14). Compared to FGS
negative women, women with FGS had similar expression profiles
of chemokines that predicted HIV-1 acquisition risk in a South
African study (MIP-1a [CCL-3], MIP-1b [CCL-4], IL-8 [CXCL-
8], and IP-10 [CXCL-10]) (8). This was confirmed after adjusting
for age, STI, community of residence, education, and use of
hormonal contraception (Figure 3). Principal Components
Analysis identified that two Principal Components accounted
for 60.0% of the variability in the data (S2 Table). Taken
forward, there was no difference in mean scores for these two
Principal Components by FGS status (S3 Figure).
When the FGS and probable FGS groups were combined, in
the crude analysis (S4 Figure) and after adjustment for possible
confounders, participants with FGS/probable FGS had higher
concentrations of TNF-a than FGS negative participants (S5
Figure, p=0.03, p-value adjusted for multiple testing 0.09).
Exploratory Analyses – Clinical
Disease Burden
In an exploratory analysis of participants (n=15) with a higher
FGS burden defined as ≥2 Schistosoma PCR positive genital
specimens, there was evidence of an elevated concentration of
cytokines IL-4, IL-5, IL-13, IL-15 compared to FGS negative
women (Figure 4). This association remained after adjusting for
potential confounders (Figure 5). After adjustment for multiple
comparisons strong evidence remained that IL-4 (multiple
testing adjusted p=0.037) and IL-5 (multiple testing adjusted
p<0.001) were associated with FGS.
Exploratory Analyses – Schistosoma
DNA Concentration
In a further exploratory analysis of women (n=15) with FGS and
moderate or high genital Schistosoma DNA concentration
(Schistosoma PCR Cq<35) there was evidence that theFrontiers in Immunology | www.frontiersin.org 7concentrations of cytokines IL-1a, IL-4, IL-5, IL-13, IL-15, and
TNF-a were elevated in participants with Schistosoma PCR
Cq<35 compared to FGS negative women (Figure 6). After
adjustment for potential confounders, evidence remained that
IL-4, IL-5, IL-15, and TNF-a were elevated in participants with
moderate/high Schistosoma DNA concentration compared to
FGS negative women (Figure 7). After adjustment for multiple
comparisons, strong evidence remained that the associations for
IL-5 (multiple testing adjusted p=0.001) and TNF-a (multiple
testing adjusted p=0.045) were unlikely to have occurred by
chance. When comparing the participants with moderate/high
Schistosoma DNA concentration and the participants with ≥2
PCR positive genital specimens, 11 women overlapped
between groups.
Sensitivity Analyses – HIV-1 and
CVL Hemoglobin
We performed sensitivity analyses removing participants with
HIV-1 infection or the presence of hemoglobin in CVL from
the comparison between FGS and negative FGS groups. When
n=31 participants with HIV-1 from the FGS and FGS negative
groups were excluded from the analysis, there was no difference in
the expression profiles of cytokines or chemokines in women with
FGS compared to FGS negative women (S6 Figure). When n=139
participants with any detectable hemoglobin in CVL were
removed from the analysis (S7 Figure), there was some evidence
that concentrations of IL-17A and IL-8 (CXCL-8) were higher in
participants with FGS (n=8) compared to the FGS negative group
(n=57) (p=0.13 after allowing for multiple testing).DISCUSSION
This study is the first to describe expression patterns of cytokines
and chemokines in human FGS, diagnosed by Schistosoma PCR
from vaginal swabs, cervical swabs, and CVL. The immune
environment in helminth infection is often characterized as T
helper 2 (Th2) biased and involves the orchestration of cytokines
(IL-4, IL-5, IL-13), antibodies, and regulatory cells (33). We did
not detect an association between FGS, defined as Schistosoma
DNA detected in genital PCR specimens, and a change inFIGURE 2 | Median with interquartile range of the log-transformed crude concentrations of eleven cytokines and six chemokines in cervicovaginal lavage of participants
with (FGS: n=28) and without female genital schistosomiasis (FGS negative: n=159) c. FGS – Schistosoma PCR positive specimen from cervicovaginal lavage, vaginal
swab or cervical swab; FGS negative – negative genital PCR and negative circulating anodic antigen and negative urine microscopy and negative expert-reviewed
colposcopy imaging. cp-value after adjustment for multiple testing with a Monte-Carlo simulation approach, p=0.14 p-value symbol legend: **p < 0.05.March 2021 | Volume 12 | Article 620657
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those associated with HIV-1 acquisition in a South African study
(8). Compared to the FGS negative participants, the Th2 cytokine
IL-5 was elevated in the participants with FGS, however after
adjustment for multiple comparisons we cannot exclude that this
finding may be due to chance.
Previous work on male genital schistosomiasis has shown that
infection intensity, defined by seminal egg count, is strongly
associated with elevated seminal cytokine concentrations
including Th2 (IL-4), regulatory (IL-10), Th1 (IFN-g) and pro-
inflammatory (TNF-a) cytokines (21). Thus, we evaluated FGS
burden by performing two exploratory analyses, the results of
which show a Th2 expression pattern. First, we investigated the
association between multiple PCR-positive genital specimens as a
potential proxy marker of higher FGS burden in 15 women with ≥
two positive genital specimens for Schistosoma DNA. We also
investigated whether Schistosoma DNA concentrations in genital
samples might be associated with a change in cytokine
concentrations in 15 participants with FGS and moderate/high
genital Schistosoma DNA concentrations (defined as Schistosoma
PCR Cq<35). After adjusting for potential confounders, the
exploratory analyses found a higher cervicovaginal Th2 cytokine
response (IL-4, IL5-, IL-13) in participants with ≥ two positive
specimens and participants with higher genital Schistosoma DNA
concentrations. This is not unexpected considering that a Th2Frontiers in Immunology | www.frontiersin.org 8biased immune response is associated with helminth infection (33)
and S. haematobium exposure in both human and murine hosts
(34, 35). There was evidence for higher concentrations of IL-5 after
adjustment for multiple comparisons across both exploratory
analyses. IL-5 induces eosinophil maturation and an IL-5
response to Schistosoma antigens has been associated with
microhematuria in children with S. haematobium infection (36).
There was evidence for higher concentrations of IL-4 after
adjustment for multiple comparisons in the exploratory analyses
of multiple PCR-positive genital specimens for Schistosoma DNA.
In the Th2 response, IL-4 directly regulates T-cell differentiation
and proliferation (37). The finding of elevated levels of pro-
inflammatory TNF-a in the exploratory analyses of participants
with moderate/high Schistosoma DNA concentrations after
adjustment for potential confounders and multiple comparisons,
suggests that FGS may promote a mixed Th2 and pro-
inflammatory response. TNF-a may be associated with
Schistosoma granuloma formation (38) and in children with S.
haematobium infection, TNF-a production has been associated
with ultrasound-determined urinary bladder morbidity (39).
We found IL-13 and IL-15 to be associated with a higher clinical
FGS burden and higher genital Schistosoma DNA concentrations
after adjusting for potential confounders, although these
associations no longer remained after adjustment for multiple
comparisons. Predominantly produced by macrophages, IL-15 isTABLE 2 | Crude and adjusted associations (with 95% confidence intervals) of FGS* status with concentrations of cytokines and chemokines in cervicovaginal
lavage**.
Analyte %(n) above LLOQ FGS Negative ‡n=159 FGS n=28 p-value‡‡ GMR FGS vs FGS Negative (n=28) † p-value † †
Linear Regression - Analytes with >70% above LLOQ
Eotaxin 73.6 (156) 3.85 3.92 0.22 1.48 (0.95–2.32) 0.08
Interferon–g 84.0 (178) 0.91 0.80 0.71 0.98 (0.64–1.51) 0.94
IL–10 90.1 (191) 0.98 1.33 0.75 1.02 (0.65–1.61) 0.93
IL–17A 93.4 (198) 1.38 1.86 0.14 1.37 (0.85–2.23) 0.64
IL1–a 99.5 (211) 44.00 73.08 0.17 1.24 (0.63–2.44) 0.19
IL1–b 93.4 (198) 9.79 9.05 0.38 1.59 (0.56–4.51) 0.52
IL–4 96.2 (204) 2.79 3.42 0.20 1.41 (0.94–2.12) 0.09
IL–6 87.7 (186) 2.85 3.81 0.67 1.14 (0.56–2.35) 0.71
IL–8 100.0 (212) 526.03 566.68 0.33 1.29 (0.75–2.19) 0.34
IP–10 100.0 (212) 101.86 128.38 0.42 1.34 (0.68–2.66) 0.39
MCP–1 100.0 (212) 29.04 24.68 0.79 0.98 (0.53–1.83) 0.95
MIP1–a 98.1 (208) 4.23 3.61 0.15 0.62 (0.36–1.08) 0.09
MIP1–b 84.0 (177) 1.32 1.64 0.67 1.05 (0.54–2.05) 0.89
Logistic Regression - Analytes with <70% above LLOQ




p-valuec OR FGS vs FGS Negativecc p-value#
IL–5 17.0 (36) 13.84 (22) 32.1 (9) 0.02 3.44 (1.30–9.05) 0.02
IL–13 32.6 (69) 32.7 (52) 35.7 (10) 0.76 1.17 (0.50–2.75) 0.72
IL–15 47.2 (100) 44.7 (71) 60.7 (17) 0.12 1.91 (0.84–4.36) 0.12
TNF–a 41.0 (87) 35.9 (57) 50.0 (14) 0.15 1.85 (0.81–4.22) 0.14March 2021 | Volume 12 | ArtFGS, female genital schistosomiasis; GMR, geometric mean ratio; LLOQ, lower limit of quantification.
*FGS – Schistosoma PCR positive specimen from cervicovaginal lavage, vaginal swab or cervical swab; FGS negative – negative Schistosoma PCR and negative circulating anodic antigen
and negative urine microscopy and negative expert-reviewed colposcopy imaging.
**Concentrations are reported in pg/ml.
‡n=25 Participants with probable FGS are not shown.
‡‡Rank sum p-value.
†Adjusted for age, STI, educational level attained, community of residence, and hormonal contraception.
††F-test p-value.
cChi-squared p-value.
ccAdjusted for age and STI.
#Likelihood ratio test p-value.icle 620657
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FIGURE 3 | Comparison of the concentration or presence of eleven cytokines and six chemokines in cervicovaginal lavage of participants with (FGS, n=28) and
without (FGS negative, n=159) female genital schistosomiasisc. (A) Concentrations of eotaxin, IFN-g, IL-1a, IL-1b, IL-4, IL-6, IL-8, IL-10, MCP-1, MIP-1a, and MIP-1b
were compared between FGS and FGS negative participants by linear regression and adjusted for age, community of residence, education, presence of sexually
transmitted infection and hormonal contraceptive use, with results shown as geometric mean ratios with 95% CI. (B) Presence/absence of IL-5, IL-13, IL-15 and
TNF-a were compared by logistic regression and adjusted for age and sexually transmitted infection, with results shown as odds ratio with 95% CI. The line at 1
indicates the value at which there is no difference between the FGS and FGS negative groups. p-value symbol legend: *p < 0.1 **p < 0.05. cfemale genital
schistosomiasis – Schistosoma PCR positive specimen from cervicovaginal lavage, vaginal swab or cervical swab; FGS negative – negative genital PCR and negative
urine circulating anodic antigen and negative urine microscopy and negative expert-reviewed colposcopy imaging.FIGURE 4 | Median with interquartile range of the log-transformed crude concentrations of eleven cytokines and six chemokines in cervicovaginal lavage by FGSc
burden (Schistosoma PCR in ≥ two genital specimens: n=15, FGS negative: n=159) cc. cFGS – Schistosoma PCR positive specimen from cervicovaginal lavage,
vaginal swab or cervical swab; FGS negative – negative Schistosoma PCR and negative circulating anodic antigen and negative urine microscopy and negative
expert-reviewed colposcopy imaging. ccp-value after adjustment for multiple testing with a Monte-Carlo simulation approach, p < 0.001. p-value legend *p < 0.1
**p < 0.05.Frontiers in Immunology | www.frontiersin.org March 2021 | Volume 12 | Article 6206579
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FIGURE 5 | Comparison of the concentrations or presence of eleven cytokines and six chemokines in cervicovaginal lavage in participants with greater FGS burden
(Schistosoma PCR positive in ≥ two genital specimens, n=15) and participants without female genital schistosomiasis (n=159) c. (A) Concentrations of eotaxin, IFN-g,
IL-1a, IL-1b, IL-4, IL-6, IL-8, IL-10, MCP-1, MIP-1a, and MIP-1b were compared between FGS and FGS negative participants by linear regression adjusted for age,
community of residence, education, presence of sexually transmitted infection and hormonal contraceptive use, with results shown as geometric mean ratios with
95% CI. (B) Presence/absence of IL-5, IL-13, IL-15 and TNF-a were compared by logistic regression and adjusted for age and sexually transmitted infection, with
results shown as odds ratio with 95% CI. The line at 1 indicates the value at which there is no difference between the FGS and FGS negative groups. p-value symbol
legend: *p <0.1 **p <0.05. cfemale genital schistosomiasis – Schistosoma PCR positive specimen from cervicovaginal lavage, vaginal swab or cervical swab; FGS
negative – negative Schistosoma PCR and negative circulating anodic antigen and negative urine microscopy and negative expert-reviewed colposcopy imaging.FIGURE 6 | Median with interquartile range of the log-transformed crude concentrations of eleven cytokines and six chemokines in cervicovaginal lavage by FGS
burden (Schistosoma DNA concentration Cq <35 in any genital specimen, n=15, FGS negative:n=159) c. FGS – Schistosoma PCR positive specimen from
cervicovaginal lavage, vaginal swab or cervical swab; FGS negative – negative Schistosoma PCR and negative circulating anodic antigen and negative urine
microscopy and negative expert-reviewed colposcopy imaging. cp-value after adjustment for multiple testing with a Monte-Carlo simulation approach, p=0.001
p-value symbol legend: *p < 0.1 **p < 0.05.Frontiers in Immunology | www.frontiersin.org March 2021 | Volume 12 | Article 62065710
Sturt et al. FGS and Cervicovaginal Immune Activationa pro-inflammatory, immunomodulatory cytokine that stimulates
T, B, and Natural Killer cells (40). Lower levels of IL-15 have been
reported in the cervicovaginal environment of women with S.
haematobium infection, with between-study differences potentially
related to genital Schistosoma DNA detection (20). The Th2
cytokine IL-13 is thought to be an important driver of collagen
deposition in the Schistosoma egg granuloma (41), ultimately
leading to fibrosis. Indeed, IL-13 expression levels have been
associated with the severity of hepatic fibrosis in S. mansoni
infection (42). The exploratory sub-group analyses thus support
previous work describing that S. haematobium may modulate the
genital immune environment (20, 21). As a protracted Th2 response
is often associated with schistosomiasis-related morbidity (43), our
study findings warrant further investigation. The current study
included many statistical tests, and these were allowed for using a
permutation testing approach. However, we cannot exclude the
possibility that some of the associations are due to chance. Thus, it
may be more instructive to consider patterns in cytokine signaturesFrontiers in Immunology | www.frontiersin.org 11(Th2, pro-inflammatory) across analyses, rather than interpreting
significance testing for any one cytokine in isolation. Although
strong evidence remained for some of the associations found in the
exploratory analyses of FGS burden after adjusting for potential
confounders and multiple comparisons, as exploratory analyses,
these findings should be viewed as hypothesis generating.
Many hypotheses have been put forward regarding the
mechanism of HIV-1 vulnerability in women with FGS, with
evidence of both local mucosal factors and systemic immuno-
modulation (2, 4–6). In a South African study, women who
acquired HIV-1 in the CAPRISA tenofovir gel trial had higher
concentrations of the chemotactic cytokines MIP1-a (CCL-3),
MIP1-b (CCL-4), IL-8 (CXCL-8), and IP-10 (CXCL-10) prior to
seroconversion than women who did not seroconvert (8). In the
current study, the concentrations of the aforementioned
chemotactic chemokines were not higher in women with FGS
compared to the FGS negative group. While not yet studied in S.
haematobium, herpes simplex virus type 2 infection stimulatesA
B
FIGURE 7 | Comparison of the concentration or presence of eleven cytokines and six chemokines in cervicovaginal lavage in participants with moderate to high
Schistosoma DNA concentrations (Cq <35 in any genital specimen, n=15) and participants without female genital schistosomiasis (n=159) c. (A) Concentrations of
eotaxin, IFN-g, IL-1a, IL-1b, IL-4, IL-6, IL-8, IL-10, MCP-1, MIP-1a, and MIP-1b were compared by linear regression adjusted for age, community of residence,
education, presence of sexually transmitted infection and hormonal contraceptive use. Results are represented by geometric mean ratios with 95% CI. (B) Presence/
absence of IL-5, IL-13, IL-15 and TNF-a were compared by logistic regression and adjusted for age and sexually transmitted infection. Results are indicated by odds
ratio with 95% CI. The line at 1 indicates the value at which there is no difference between the FGS and FGS negative groups. p-value symbol legend: * <0.1,
** <0.05. cFemale genital schistosomiasis – Schistosoma PCR positive specimen from cervicovaginal lavage, vaginal swab or cervical swab; FGS negative – negative
Schistosoma PCR and negative circulating anodic antigen and negative urine microscopy and negative expert-reviewed colposcopy imaging.March 2021 | Volume 12 | Article 620657
Sturt et al. FGS and Cervicovaginal Immune ActivationTNF-a production in dendritic cells, enhancing the expression of
the chemokine co-receptor CCR5 and stimulating HIV-1
replication (44). Further research is needed to elucidate
mechanisms for the association of FGS with HIV-1 vulnerability,
and these may include schistosome-related impact on mucosal and
systemic immunity, including the activation of CD4 trafficking to
the genital mucosa (45), or modification in systemic (46) or cervical
(20) gene expression, specifically related to the regulation of
transcription, the inflammatory response or tissue fibrosis.
Cervical tissue containing S. haematobium eggs is more
vascular (4) compared to non-egg containing tissue. Clinically,
these abnormal blood vessels can be found encircling sandy
patches and contact bleeding has been associated with FGS (47).
Thus, FGS studies using cervicovaginal lavage are likely to be
burdened by the presence of hemoglobin (48). Since HIV-1 and
the presence of hemoglobin in CVL are potentially on the causal
pathway between FGS and a change in cytokine or chemokine
concentrations, we were unable to adjust for these possible
confounding variables in a multivariable model. A sensitivity
analysis removing participants with HIV-1 showed no change in
the association between FGS and cytokine or chemokine
concentrations. HIV-1 infection modulates the cervicovaginal
immune environment in women with detectable cervicovaginal
HIV-1 RNA (49) and we did not have complete data on plasma
viral load in this cohort. Additionally, the analysis to remove
participants with any CVL hemoglobin detection was limited by
loss of power. Once participants who had any CVL hemoglobin
were removed from the analysis, there was evidence of higher
concentrations of IL-17A and IL-8 (CXCL-8) in participants
with FGS (n=8) compared with FGS negative participants
(n=57). This finding, however, was less robust after adjusting
for multiple comparisons. Considering the potential loss of the
FGS phenotype when excluding women with CVL hemoglobin
and the small and likely non-representative sample size, these
findings should be interpreted with caution.
Our study has a number of strengths. We are the first to
describe the cervicovaginal immune environment in women with
Schistosoma PCR-defined FGS and this study illustrates the
importance of evaluating FGS burden. Defining FGS based on
the detection of Schistosoma DNA in the female genital tract by
PCR results provides a higher certainty of genital involvement and
a quantitative reference standard compared to visually-diagnosed
FGS or the use of urine diagnostics alone. Due to the small
numbers of FGS cases, we employed a matching strategy
wherein participants with FGS were frequency matched with
FGS negative participants. To reduce the risk of selection bias,
we used a random number generator to randomly select controls
and matched on age group. Multiplex bead-based assays have a
precedent for use in CVL (8, 11, 14, 17) and we examined a variety
of soluble immune proteins including chemokines, Th1, Th2, pro-
inflammatory and regulatory cytokines for a broad overview of the
cervicovaginal immune environment. Another strength is that we
present both crude and adjusted outcomes to facilitate
comparisons in future study settings.
While our study has multiple strengths, there are also some
relevant limitations. The study was conducted in a low-prevalenceFrontiers in Immunology | www.frontiersin.org 12area and the number of FGS cases in the main and exploratory
analyses is small. We selected a sub-sample of the cohort for
multiplex bead-based immunoassays. This may limit the
generalizability of the proportions presented for demographic
variables or FGS and schistosomiasis prevalence. Secondly, we
were unable to measure a number of behavioral and biological
factors that also affect cervicovaginal soluble immune protein
expression patterns including the presence of bacterial vaginosis
(13), HSV-2 status (11), intra-vaginal cleansing practices (17),
vaginal pH, menstrual cycle phase (18), body weight (50) and
recent sexual contact (16). It is also undetermined how these same
factors may influence Schistosoma DNA concentrations. Thus, we
cannot exclude unmeasured and residual confounding.
Additionally, due to the cross-sectional study design, we were
also unable to assess the long-term impact of the cytokine
expression profiles or to determine the duration of FGS
infection. Though the cytokines and chemokines we measured
are well-known biomarkers for inflammation and disease, it is a
limitation that we did not have companion flow cytometry, biopsy,
or transcriptomic data for a more detailed evaluation of cellular
and histological processes. Additionally, CVL is dilute and the
concentrations of the cytokines and chemokines we measured were
small. This could potentially be ameliorated in future studies with
the use of a menstrual cup to collect genital fluid (51).
FGS is thought to be a chronic infection of the female genital
tissue, with initial infection and the development of genital lesions
occurring during childhood water contact (52) that persist into
adulthood, often even despite treatment with praziquantel (53).
The chronicity of FGS lesions may have an impact on the
cervicovaginal immune environment and a longitudinal study is
needed to document the FGS immune environment in a spectrum
of FGS stages before interventions can be based on our exploratory
observations. Further work investigating the cervicovaginal
immune environment in FGS may impact diagnostic,
preventative, and therapeutic options as well as potentially
providing additional information on HIV-1 vulnerability.
In conclusion, this study does not show a difference in the
cervicovaginal immune environment by Schistosoma PCR-
defined FGS status. However, two exploratory analyses suggest
that there may be a relationship between higher genital
Schistosoma DNA concentrations or multiple PCR positive
genital specimens and a Th2 and pro-inflammatory
modulation of the cervicovaginal immune environment, as
measured by elevated cytokine concentrations. FGS may alter
the female genital tract immune environment, but a larger
longitudinal study in a high FGS prevalence area is needed to
better define the role of FGS in HIV-1 acquisition.DATA AVAILABILITY STATEMENT
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